Ishita Drugs & Industries Limited has submitted a regulatory disclosure to BSE Limited regarding an acquisition of shares by its related party, Ishita Pharmaceuticals.
The disclosure is made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Transaction Details
- Acquirer: Ishita Pharmaceuticals (related party of Ishita Drugs and Industries Limited)
- Target Company: Ishita Drugs and Industries Limited
- Number of Shares Acquired: 55 equity shares of ₹10 each
- Mode of Acquisition: Open Market
- Date of Acquisition: June 19, 2026
Shareholding Changes
Before Acquisition (Ishita Pharmaceuticals Holding):
- Shares carrying voting rights: 32,642
- Percentage of total share/voting capital: 1.09%
- Percentage of total diluted share/voting capital: 1.09%
- No shares were encumbered (pledge/lien/non-disposal undertaking)
- No voting rights otherwise than by shares
- No warrants/convertible securities/other instruments
Acquisition Details:
- Shares carrying voting rights acquired: 55
- Percentage change: 0.00% (increase from 1.09% to 1.09%)
After Acquisition (Ishita Pharmaceuticals Holding):
- Shares carrying voting rights: 32,697
- Percentage of total share/voting capital: 1.09%
- Percentage of total diluted share/voting capital: 1.09%
- No shares are encumbered
- No voting rights otherwise than by shares
- No warrants/convertible securities/other instruments
Capital Structure Impact
- Equity share capital before acquisition: ₹2,99,03,000 (29,90,300 shares of ₹10 each)
- Equity share capital after acquisition: ₹2,99,03,000 (29,90,300 shares of ₹10 each)
- Total diluted share/voting capital after acquisition: ₹2,99,03,000 (29,90,300 shares of ₹10 each)
The transaction represents a minimal change in ownership structure without altering the company's total equity capital.